Tag Archive for: from SATT AxLR

Spima Therapeutics
Partnership

Spima Therapeutics starts with global licence agreement

SPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001

Read more